{
  "id": 610711,
  "title": "Hims & Hers planning to sell compounded peptides",
  "url": "https://urgent.news/2026/08/11/hims-hers-planning-to-sell-compounded-peptides",
  "topic": "world",
  "section": "World",
  "published": "2026-08-11T22:06:55.000Z",
  "source": {
    "name": "The Hill",
    "slug": "the-hill",
    "url": "https://thehill.com/policy/healthcare/6023657-hims-hers-plans-compounded-peptides/"
  },
  "original_language": "en",
  "account": null,
  "summary": "Hims & Hers Health is planning to sell compounded peptides, the company said in a Monday earnings call. The company’s CEO, Andrew Dudum, said in the earnings call that it was “currently developing a best-in-class peptides experience, including U.S. manufactured products, clinical-led guidance, and ongoing blood testing.” Dudum said in the call that the company...",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}